The Indian healthcare company is planning take on external investors for a new fund that would continue its corporate venture capital investments.
Cipla, an India-based pharmaceutical company best known for producing low-cost AIDS drugs, plans to raise a new fund for its corporate venturing unit, Cipla New Ventures (CNV), Business Standard has reported.
CNV has generated interest from external investors but the legal structure of the new fund has not yet been finalised.
The unit has made four investments so far, in Stempeutics, Chase Pharma, MabPharma and BioMab, and is operating three incubators: Ciptec, Biologicals and Consumer Healthcare.
The fund would be…
